PC
CASC

PointState Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

PointState Capital’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-83,333
Closed -$1.03M – 188
2013
Q3 		$1.03M Buy
+83,333
New +$877K 0.02% 127

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

PointState Capital's CASC Position: Q4 2013 in Review

PointState Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2013, closing a stake of 83,333 shares — an estimated $1.03M sold.

PointState Capital first reported a position in CASC in Q3 2013 and held it in 1 quarter. The position peaked at $1.03M in Q3 2013. 67 funds tracked by Wall St. Rank hold CASC as of Q4 2013.

  • PointState Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • PointState Capital sold 83,333 Cascadian Therapeutics, Inc. shares in Q4 2013, an estimated $1.03M.
  • PointState Capital first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • PointState Capital's Cascadian Therapeutics, Inc. position peaked at $1.03M in Q3 2013.
  • 67 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2013.

Based on PointState Capital's 13F filing for Q4 2013, filed 14 Feb 2014.